Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Payables (2016 - 2026)

Usana Health Sciences has reported Payables over the past 16 years, most recently at $16.2 million for Q2 2026.

  • Quarterly Payables rose 16.14% to $16.2 million in Q2 2026 from the year-ago period, while the trailing twelve-month figure was $16.2 million through Apr 2026, up 16.14% year-over-year, with the annual reading at $17.3 million for FY2026, 44.05% up from the prior year.
  • Payables was $16.2 million for Q2 2026 at Usana Health Sciences, down from $17.3 million in the prior quarter.
  • Over five years, Payables peaked at $17.9 million in Q2 2025 and troughed at $6.6 million in Q2 2024.
  • The 5-year median for Payables is $10.8 million (2022), against an average of $11.7 million.
  • Year-over-year, Payables decreased 28.31% in 2024 and then soared 169.24% in 2025.
  • A 5-year view of Payables shows it stood at $11.0 million in 2022, then fell by 8.86% to $10.1 million in 2023, then grew by 19.01% to $12.0 million in 2024, then soared by 35.34% to $16.2 million in 2025, then increased by 0.07% to $16.2 million in 2026.
  • Per Business Quant, the three most recent readings for USNA's Payables are $16.2 million (Q2 2026), $17.3 million (Q1 2026), and $16.2 million (Q3 2025).